EP4469019A1 - Inhaltsstoff zum schutz der haut und/oder schleimhäute vor virulenzfaktoren - Google Patents

Inhaltsstoff zum schutz der haut und/oder schleimhäute vor virulenzfaktoren

Info

Publication number
EP4469019A1
EP4469019A1 EP23706401.9A EP23706401A EP4469019A1 EP 4469019 A1 EP4469019 A1 EP 4469019A1 EP 23706401 A EP23706401 A EP 23706401A EP 4469019 A1 EP4469019 A1 EP 4469019A1
Authority
EP
European Patent Office
Prior art keywords
derivatives
cosmetic
skin
advantageously
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23706401.9A
Other languages
English (en)
French (fr)
Inventor
Valérie ANDRE
Isabelle Bonnet
Manon GAULT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Beauty Care Solutions France SAS
Original Assignee
BASF Beauty Care Solutions France SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF Beauty Care Solutions France SAS filed Critical BASF Beauty Care Solutions France SAS
Publication of EP4469019A1 publication Critical patent/EP4469019A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/733—Alginic acid; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to the field of cosmetics and the pharmaceutical field, in particular dermatology.
  • the present invention relates most particularly to a novel combination of pullulan and/or its derivatives in combination with
  • a polysaccharide chosen from the group consisting of hyaluronic acid, one of its salts or derivatives, alginic acid, one of its salts or derivatives and a mixture of these and
  • lactic acid one of its salts or derivatives
  • succinic acid one of its salts or derivatives
  • sucrose one of its salts or derivatives.
  • This new combination is composed of a mixture of compounds having a synergistic action making it possible to limit and/or reduce the virulence of Cutibacterium acnes, in particular the formation of the biofilm and thus prevent and/or reduce the uncomfortable and/or unpleasant manifestations and/or or unsightly virulence factors of Cutibacterium acnes. It also makes it possible to treat the pathologies associated with/due to the virulence of C. acnes, in particular to the virulence factors of Cutibacterium acnes, such as acne.
  • the skin is the largest organ in the human body. It plays a major role in protection against external attacks such as environmental attacks, climatic attacks, pollution, allergens and pathogenic germs.
  • the skin also represents a complex ecosystem on which several types of microorganisms such as bacteria and fungi proliferate. These microorganisms constitute the cutaneous flora, also called cutaneous microbial flora.
  • cutaneous flora also called cutaneous microbial flora.
  • Propionibacterium acnes otherwise known as Cutibacterium acnes, which normally lives on the skin. Under certain conditions, certain strains of C. acnes can become more virulent and therefore cause pathologies.
  • Cutibacterium acnes when it expresses virulence factors can indeed be the cause of unsightly and/or unpleasant and/or uncomfortable manifestations such as redness, swelling or even pimples and a burning sensation and/or localized heat accompanied pain, pigment spots or scars, for example following acne and therefore uneven skin tone. It can also contribute to real skin pathologies such as acne. The alteration caused at the level of the cutaneous barrier by C. acnes can also contribute to real opportunistic infections by other bacteria and/or mycoses such as candidiasis. Cosmetic or dermatological solutions are already known to act on bacteria, for example antiseptics. However, their modes of action are not targeted because they are not directed against a specific strain of microorganism.
  • Antibiotics are then a solution making it possible to act on a targeted group of the cutaneous microbial flora, but these have the disadvantages of not always being tolerated, of inducing the development of resistance and of acting on the commensal microbial flora, which can also result in the appearance of mycoses. Consequently, there is a great need in the field of cosmetics and dermatology to provide alternative active ingredients having a targeted action on a particular microbial strain, which are readily available and do not have the drawbacks or side effects previously described.
  • - pullulan and/or one of its derivatives - a polysaccharide chosen from the group consisting of hyaluronic acid, one of its salts or derivatives, alginic acid, one of its salts or derivatives, and a mixture thereof
  • one of its salts or derivatives had the ability to limit and/or reduce the virulence of strains of Cutibacterium acnes, in particular by at least one of the following mechanisms:
  • Sucrose has also been described as promoting the specific fermentation of S. epidermidis, which will produce succinic acid, a compound that belongs to the family of short-chain fatty acids. (short-chain fatty acids (SCFAs)) and described in the literature as inhibiting the growth of C. acnes.
  • SCFAs short-chain fatty acids
  • the inventors discovered that the new combination according to the invention exhibited synergistic effects against the virulence factors of C. acnes.
  • the effect of the combination according to the invention on the formation of the biofilm of C acnes is in fact greater than the effect obtained on the one hand with the mixture described in the previous patent application published under the number FR3064473A1 and on the other share higher than that obtained with a mixture of sucrose, lactic and succinic acid.
  • This synergistic action of the compounds of the new combination according to the invention is demonstrated in example 2.
  • the present invention therefore relates to a combination comprising:
  • a polysaccharide chosen from the group consisting of hyaluronic acid, one of its salts or derivatives, alginic acid, one of its salts or derivatives, and mixtures thereof, and
  • the combination may be in the form of a mixture of the compounds listed above and consist only of these compounds, or may be in the form of a mixture of cosmetic or pharmaceutical ingredients, in particular dermatological by example when the combination is combined with xanthan gum and/or glycerin and/or pentylene glycol and/or caprylyl glycol and/or water, advantageously xanthan gum and/or glycerine.
  • the combination may alternatively be in the form of a cosmetic or pharmaceutical, in particular dermatological, composition.
  • the present invention also relates to the cosmetic use of this combination or of the mixture of cosmetic ingredients or of a cosmetic composition comprising the combination according to the invention for limiting and/or reducing the virulence of strains of Cutibacterium acnes on the skin and/or or the mucous membranes, in particular by at least one of the following mechanisms:
  • C. acnes can be responsible for unsightly and/or unpleasant and/or uncomfortable manifestations which are not diseases but which one wishes to avoid for aesthetic and/or comfort reasons such as :
  • the virulence factors of C. acnes can also contribute, in the most serious cases and under multifactorial favorable conditions, to the appearance of pathologies of the skin and/or mucous membranes, such as bacterial infections of the skin and /or mucous membranes, pustules, papules, boils, folliculitis, abscesses, and/or acne, in particular superinfected, and/or delay in the healing of wounds and even their superinfection and/or inflammation of the skin and/or mucous membranes. They can also contribute to the appearance of scar marks on the skin in the form of pigment spots and/or acne scars.
  • the area of skin on which treatment using the combination according to the invention, optionally in the form of a mixture of cosmetic or pharmaceutical ingredients or of a cosmetic or pharmaceutical composition, is particularly useful is the area of skin or mucous membrane showing a large amount of C. cutaneous and/or mucosal acne such as the face, in particular the neck, chin, nose, forehead, cheeks, shoulders, arms, back, torso; and/or the area of skin or mucous membrane whose skin barrier has been altered, for example due to a mechanical, chemical or biological action, such as by sunburn (solar erythema), by the action of the razor, by the use of unsuitable or overly astringent cleaning products, pollution, the use of antibiotics, allergens, etc.
  • a mechanical, chemical or biological action such as by sunburn (solar erythema), by the action of the razor, by the use of unsuitable or overly astringent cleaning products, pollution, the use of antibiotics, allergens, etc.
  • These may thus be irritated areas, weakened areas, shaved areas, inflamed areas, scars and/or wounds.
  • the combination according to the invention comprises pullulan and a polysaccharide chosen from alginic acid and/or hyaluronic acid, their salts and/or derivatives.
  • the polysaccharide is propylene glycol alginate, sodium hyaluronate and/or mixtures thereof.
  • Pullulan is a natural polysaccharide (saccharide polymer) made up of units of maltotriose (a trisaccharide of glucose), also known as a-l,4-a-l,6-glucan.
  • maltotriose a trisaccharide of glucose
  • the three glucose units that make up maltotriose are linked by an ⁇ -1,4 type saccharide bond, while the maltotrioses are connected to each other by ⁇ -1,61 type saccharide bonds.
  • Pullulan is produced from starch by the fungus Aureobasidium pullulans and can be obtained from different ferments of A'ureobasidium pullulans. According to the present invention, pullulan can be used in its aqueous, optionally saline form.
  • the pullulan derivatives that can be used in the context of the present invention are cosmetically and/or pharmaceutically acceptable derivatives, preferably dermatologically acceptable, that is to say they are non-toxic for administration to humans, in particular by application topical and can be applied without risk and without causing an allergic or inflammatory reaction, especially on the skin.
  • the pullulan derivatives are chosen from organomineral derivatives based on silicon normally used in cosmetics, such as for example those chosen from trimethylsiloxysilylcarbamoyl pullulan and trimethylsilyl pullulan.
  • the pullulan is not in the derivative form.
  • pullulan has a weight-average molecular weight, advantageously measured by exclusion chromatography steric, less than 500 kDa, advantageously about 200 kDa.
  • Pullulan is commercially available (Chemaster International, China; Hayashibara, Japan).
  • Hyaluronic acid its salts and derivatives are among the best known and most widely used moisturizing active ingredients today.
  • Hyaluronic acid is a polymer of disaccharides, themselves composed of D-glucuronic acid and D-N-acetylglucosamine, linked together by alternating beta-1,4 and beta-1,3 glycosidic bonds. It is therefore a natural glycosaminoglycan. It is one of the main components of the extracellular matrix. Its different fractions, depending on their molecular weights, can be used as a moisturizing agent as described in patent application US2008/0003271.
  • Alginic acid and its derivatives are natural polysaccharides obtained from a family of brown algae: laminaria or fucus.
  • Alginate is a polymer formed from two monomers bonded together: mannuronate or mannuronic acid, some of which are acetylated, and guluronate or guluronic acid. Linking is via beta 1-4.
  • Alginates are used as thickeners, gelling agents, emulsifiers and stabilizers of the most varied industrial products. They are also known to have water retention properties.
  • the alginic acid will be in the form of propylene glycol alginate, to facilitate the formulation and use of the combination and compositions containing it.
  • pullulan is in combination with alginic and/or hyaluronic acid as described in application WO2014027163.
  • the “derivatives” are preferably esterified derivatives and organomineral derivatives based on silicon.
  • esterified derivatives of one of the compounds in particular pullulan, hyaluronic acid, alginic acid, succinic acid, lactic acid or sucrose, all derivatives obtained by single or multiple esterification of a primary or secondary alcohol function or of an acid function of the compound, and having on the esterified part a carbon chain comprising from 1 to 6 carbon atoms, advantageously a linear or branched alkyl chain.
  • organomineral derivatives based on silicon of pullulan, hyaluronic acid or alginic acid means all the derivatives which contain at least one silanol (-SiOH) and obtained by condensation of pullulan, hyaluronic acid or alginic acid with a molecule from the silane family.
  • the salts and derivatives of hyaluronic acid that can be used in the context of the present invention are cosmetically and/or pharmaceutically acceptable salts or derivatives, preferably dermatologically acceptable.
  • the hyaluronic acid salts are chosen from hydrolyzed calcium hyaluronate, hydrolyzed sodium hyaluronate, potassium hyaluronate, sodium hyaluronate, sulfated sodium hyaluronate and mixtures thereof.
  • it is sodium hyaluronate.
  • the derivatives of hyaluronic acid are chosen from the derivatives usually used in cosmetics such as, for example, those chosen from esterified derivatives, in particular ascorbyl hyaluronate, benzyl hyaluronate, propylene glycol hyaluronate, acetylated sodium hyaluronate, sodium butyroyl hyaluronate or hydroxypropyltrimonium hyaluronate, organomineral silicon derivatives, in particular dimethylsilanol hyaluronate and mixtures thereof.
  • esterified derivatives in particular ascorbyl hyaluronate, benzyl hyaluronate, propylene glycol hyaluronate, acetylated sodium hyaluronate, sodium butyroyl hyaluronate or hydroxypropyltrimonium hyaluronate, organomineral silicon derivatives, in particular dimethylsilan
  • the hyaluronic acid is in the form of one of its salts.
  • it is sodium hyaluronate.
  • hyaluronic acid, its salts or esterified derivatives have a weight-average molecular weight, advantageously measured by steric exclusion chromatography, greater than 20 kDa, advantageously between 50 and 800 kDa, advantageously between 250 and 450 kDa.
  • Sodium hyaluronate is commercially available in particular from the companies Technidd Chemi-tech, Wuhan Fortuna Chemical, Dalian Chem lmp. and Exp.
  • the salts and derivatives of alginic acid that can be used in the context of the present invention are cosmetically and/or pharmaceutically acceptable salts or derivatives, preferably dermatologically acceptable.
  • the salts of alginic acid are chosen from ammonium alginate, sodium alginate, calcium alginate, magnesium alginate, sodium sulphate alginate and potassium alginate.
  • it is sodium alginate.
  • the derivatives of alginic acid are chosen from derivatives usually used in cosmetics such as, for example, those chosen from esterified derivatives, in particular glyceryl alginate or propylene glycol alginate, organomineral derivatives silicon alginic acid, in particular siloxanetriol alginate or methylsilanol carboxymethyl theophylline alginate, and mixtures thereof.
  • the derivative is propylene glycol alginate.
  • the alginic acid is in the form of one of its salts.
  • it is sodium alginate.
  • alginic acid, its salts or derivatives, in particular esterified or organomineral silicon have a weight-average molecular weight, advantageously measured by size exclusion chromatography, of between 10 and 600 kDa, preferably between 30 and 550 kDa, more preferably from 100 to 550 kDa.
  • Sodium alginate is commercially available in particular from the companies Laserson SA, Univar, Danisco Ingredients. BASF, BAM, Penta Manufacturing Company, Vevy Europe.
  • the alginic acid will be in the form of propylene glycol alginate or mixtures thereof.
  • the ratio by weight of pullulan, or derivatives and the polysaccharide is within the range 1/0.002 - 1/200, advantageously in the range 1/0.2 - 1/20, even more advantageously in the range 1/1 - 1/3.
  • the combination according to the invention contains a mixture of pullulan, optionally in the form of a derivative, and hyaluronic acid, optionally in the form of a salt or derivative, in particular esterified, advantageously in the form of hyaluronate of sodium.
  • hyaluronic acid, salts or in particular esterified derivatives will be between 0.00 lx and lOOx.
  • the ratio by weight pullulan, or derivatives in particular esterified/hyaluronic acid, salts or derivatives in particular esterified is included in the range 1/0.001 -1/100, advantageously in the range 1/0.1 - 1/10, again more preferably it is 1/1.
  • the combination according to the invention contains a mixture of pullulan, optionally in the form of a derivative, and alginic acid, optionally in the form of a salt or derivative, in particular esterified, advantageously in the form of alginate of propylene glycol.
  • the quantity of alginic acid, salts or derivatives in particular esterified will be between 0.00 lx and lOOx.
  • the ratio by weight pullulan or derivatives in particular esterified/alginic acid, salts or derivatives in particular esterified is included in the range 1/0.001 - 1/100, advantageously in the range 1/0.1 - 1/10, even more advantageously included in the range 1/1 - 1/2.
  • the combination according to the invention contains a mixture of pullulan, optionally in the form of a derivative, of hyaluronic acid, optionally in the form of a salt or in particular an esterified derivative, advantageously in the form of sodium hyaluronate , and alginic acid, optionally in the form of a salt or in particular an esterified derivative, advantageously in the form of propylene glycol alginate. It therefore includes these three compounds.
  • the combination according to the invention therefore comprises pullulan, sodium hyaluronate and propylene glycol alginate.
  • the ratio by weight of pullulan optionally in the form of derivatives/hyaluronic acid, salts or esterified derivatives,/alginic acid, salts or esterified derivatives, is included in the range 1/0.001/0.001 to 1/100/100, again advantageously in the range 1/0, 1/0.1 to 1/10/10, even more advantageously in the range 1/1/1 to 1/10/10, and even more preferably in the range 1/1/1 to 1/2/5.
  • this ratio is approximately 1/1/2, more preferably it is
  • said combination according to the invention forms a pluristratified molecular network, corresponding to a molecular mesh with formation of hydrogen bonds, when the 3 pullulan compounds, optionally in the form of derivatives, hyaluronic acid, salts or esterified derivatives, and alginic acid, salts or esterified derivatives are combined concomitantly, preferentially in the form of a premix, preferentially at a ratio lying in the range 1/1/1 to 1/10/10, and still preferentially in the range 1/1/1 to 1/2/5, advantageously a ratio of 1/1/2.
  • this combination in particular when it comprises the three compounds: pullulan, optionally in the form of derivatives, hyaluronic acid, salts or esterified derivatives, and alginic acid, salts or esterified derivatives, in fact has a reinforced activity, so durable, and this in particular due to the formation of a molecular network when the 3 pullulan compounds, possibly in the form of derivatives, hyaluronic acid, salts or esterified derivatives, and alginic acid, salts or esterified derivatives, are combined concomitantly, preferentially in the form of a premix, preferentially at a ratio lying in the range 1/1/1 to 1/10/10, and more preferentially in the range 1/1/1 to 1/2/5, advantageously a ratio of 1/1/2.
  • Succinic acid or 1,4-dioic butane acid can be used in its forms of acid molecule or of salts and/or derivatives, in particular esters, compatible with cosmetic and/or pharmaceutical use.
  • succinic acid salts mention may be made of monosodium or disodium succinate.
  • the succinic acid derivatives mention may be made of the cholesterol ester: cholesterol succinate.
  • Succinic acid can in particular be extracted from sugar cane by a biotechnological extraction process.
  • succinic acid optionally in the form of one of its salts and/or derivatives, is present in the combination at a content of 0.1% to 10%, preferably between 1% and 5%, again preferably 2% by weight of dry matter relative to the total weight of the combination.
  • the succinic acid is present in the combination at a ratio by weight of succinic acid, salts or derivatives/lactic acid, salts or derivatives lying in the range 1/2 to 1/ 5, preferably 1/3 to 1/4.
  • Lactic acid or 2-hydroxypropanoic acid can be used in its forms of acid molecule or of salts and/or derivatives in particular esters compatible with cosmetic and/or pharmaceutical use.
  • lactic acid salts mention may be made of sodium lactate, potassium lactate, magnesium lactate and zinc lactate.
  • esterified derivatives in particular isostearyl, stearyl and ethyl lactate.
  • Lactic acid can in particular be extracted from beets by a biotechnological extraction process
  • lactic acid optionally in the form of one of its salts and/or derivatives, is present in the combination at a content of 1% to 15%, preferably between 3% and 9%, more preferably 6, 75% by weight of dry matter relative to the total weight of the suit
  • the lactic acid is present in the combination at a ratio by weight of lactic acid, salts or derivatives / sucrose, salts or derivatives lying in the range 1/1 to 1/3 , preferably 1/1 to 1/2.
  • sucrose otherwise known as sucrose can be used as it is or in the form of a salt or a derivative compatible with cosmetic and/or pharmaceutical use.
  • the salts mention may be made of sucrose octosulfate salts, in particular potassium sucrose octosulfate.
  • sucrose esters or sucrose esters
  • fatty acids such as sucrose palmitate, sucrose cocoate, sucrose laurate, sucrose polystearate, sucrose polyoleate.
  • Sucrose can in particular be extracted from beets by a biotechnological extraction process.
  • sucrose optionally in the form of one of its salts and/or derivatives, is present in the combination at a content of 1% to 15%, preferably between 3% and 9%, even more preferably 7.5 % by weight of dry matter relative to the total weight of the combination.
  • succinic acid, lactic acid and sucrose are present in the combination at a ratio by weight of succinic acid, salts or derivatives/lactic acid, salts or derivatives/ sucrose, salts or derivatives lying in the range 1/2/2 to 1/4/15, preferably 1/3/3 to 1/4/8.
  • the term “combination” means the fact that the compounds (pullulan, alginic acid and/or hyaluronic acid, lactic acid, succinic acid and sucrose, optionally in the form of their respective salts and/or derivatives) are used together, preferably in the form of a premix.
  • the compounds pullulan, alginic acid and/or hyaluronic acid, lactic acid, succinic acid and sucrose, optionally in the form of their respective salts and/or derivatives
  • the term “cosmetic use” means a non-therapeutic use, that is to say which is not intended for therapeutic use and is intended and/or applied to a so-called healthy part of the body. , in particular on an area of the skin and/or mucous membranes, said to be healthy.
  • the term “skin” means any part of the body and/or of the face, including the scalp.
  • mucosa(s) means the mucous membranes on which C acnes are present, in particular the ocular mucosa, the nasal mucosa, the oral mucosa, in particular the labial buccal mucosa and/or the gingival mucosa , preferentially, the ocular and/or oral mucosa, and even more preferentially, the labial and/or ocular mucosa.
  • the term “healthy skin and/or healthy mucous membranes” or “healthy tissue” means an area of skin, appendix or mucosa, on which the combination or mixture of ingredients or the composition according to the invention and which is said to be "non-pathological" by a dermatologist, that is to say not showing any infection, in particular bacterial, scar, disease or skin condition such as candidiasis or dermatophytosis, impetigo, psoriasis, eczema, acne, ulcers, herpes or dermatitis, couperose, telangiectasias, solar elastosis and/or cutis laxa pathology or wounds or wounds, boils, pustules, papules, folliculitis, abscesses , sycosis, inflammation, erythema, in particular diaper rash, ecthyma, erysipelas, scar marks, in particular pigment spots and
  • the adhesion to the skin and/or mucous membranes of C. acnes can be measured as described in Example 3.
  • Biofilm production by C. acnes can be measured as described in Example 2.
  • the effect of a product on the virulence of C. acnes is thus evaluated by measuring the adhesion to the skin and/or the mucous membranes of C. acnes and/or by measuring the production of biofilm by C. acnes in the presence of the product tested and comparing the results to those obtained in the absence of the product tested.
  • the reduction in the virulence of C. acnes, preferentially in the adhesion to the skin and/or the mucous membranes of C. acnes and/or in the production of biofilm by C. acnes is at least 10% , preferably at least 20%, more preferably 30% compared to the results obtained without treatment.
  • preventing and/or reducing unsightly and/or unpleasant and/or uncomfortable manifestations due to the virulence of C. acnes is understood here to prevent the appearance of unsightly and/or unpleasant and/or uncomfortable manifestations and/or reduce them extent in terms of healthy skin, healthy hair and/or healthy body hair and/or healthy mucous membranes, and not preventing or treating a pathology. It is therefore a cosmetic use and not a therapeutic treatment.
  • the cosmetic use according to the invention is to prevent and/or reduce and/or eliminate the unsightly and/or unpleasant and/or uncomfortable manifestations due to the virulence of C. acnes, in particular for preventing and/or reducing and/or delaying the secretion of sebum and its unsightly and/or unpleasant and/or uncomfortable manifestations, in particular to prevent and/or reduce and/or delay the formation of blackheads and/or comedogenesis, and /or prevent and/or reduce the visibility of skin pores, and/or maintain and/or improve the uniformity and/or radiance and/or luminosity of the complexion of the skin and/or mucous membranes, for example by removing and /or reduction of redness and/or irregularities, and/or prevention and/or to treat the sensation of heating of the skin and/or mucous membranes, and/or to prevent and/or reduce hair loss and/or body hair, and/or to prevent and/or reduce dandruff.
  • reducing the visibility of skin pores means tightening skin pores, that is to say reducing the opening diameter of the pores, and/or the density and/or the area of the pores at the surface of the skin, and/or prevent the dilation of the skin pores.
  • the combination according to the invention in fact makes it possible to reduce the opening and/or the density of the pores at the surface of the skin.
  • the visibility of the pores of the skin can be demonstrated in vivo by a so-called “scoring” evaluation by a dermatologist on a predefined zone after application of a composition comprising the combination according to the invention. It can also be highlighted by an objective instrumental method by image analysis used to extract and quantify specific parameters of high-resolution photographs in cross-polarized configuration of the face of volunteers before and after application of a composition comprising the combination according to the invention.
  • the density of skin pores can also be measured in vivo by imaging, in particular by the fringe projection technique, by measuring the so-called curvature parameter.
  • the combination according to the invention is in an effective amount to reduce the visibility of the pores of the skin by at least 10%, preferably by at least 20%, after 28 days of application of a cream comprising the combination according to the invention, preferably formulated in the form of a cosmetic composition such as that described in the examples.
  • the measurement of the homogeneity, the radiance and/or the luminosity of the complexion of the skin can for example be measured by chromametry or by image analysis.
  • This last in vivo measurement method consists of taking high resolution photographs in a crossed polarized configuration of the face of volunteers taken at 45° before and after application of the product tested. Based on these digital photographs, an image analysis makes it possible to extract and quantify specific parameters (for example: L*, a*, b*, C, h°) related to color, brightness, the homogeneity, and the texture of the skin.
  • the term “reduce the loss of hair and/or body hair” means to reduce by at least 0.5%, preferentially by at least 1%, even more preferentially by at least 2% the density of hair or hair in telogen phase, that is to say in the falling phase.
  • the measurement of the density of hair and/or body hair in the telogen phase and in the anagen phase can be measured by in vivo measurement, by the phototrichogram technique, in the presence of the combination according to the invention or of a composition comprising it, in particular a formulation in the form of a shampoo, in comparison with the density of hair or body hair in the telogen and anagen phase measured without the combination according to the invention or without a composition comprising it.
  • the combination is applied topically, advantageously on specific parts of the body chosen the body, the face, in particular the forehead, the cheeks, the nose the so-called "T" zone (forehead, nose and chin), neck and lip contour, scalp, shoulders, arms, back, chest, Vietnameselleté, mucous membrane ocular, the nasal mucosa, the oral mucosa, in particular the labial buccal mucosa and/or the gingival mucosa, the excessively cleaned areas and/or the area of skin or mucous membrane whose skin barrier has been altered, for example due to a mechanical, chemical or biological action, such as by sunburn (erythema solar), by the action of the razor, by the use of unsuitable or too astringent cleaning products, by pollution, by the use of antibiotics , allergens, etc.
  • a mechanical, chemical or biological action such as by sunburn (erythema solar), by the action of the razor, by the use of unsuitable or too astringent cleaning products, by pollution
  • topical route is understood to mean the application of the combination and/or of the composition and/or of the mixture of ingredients according to the invention on the surface of the skin and/or of the mucous membranes , in particular by direct application or by vaporization.
  • cosmetic and/or pharmaceutical ingredient(s) means one or more plant extracts and/or one or more natural or synthetic molecules and/or mixtures thereof intended for cosmetic and/or pharmaceutical application.
  • Cosmetic ingredients are notably defined by the International Nomenclature of Cosmetic Ingredients (INCI).
  • cosmetic or pharmaceutical active ingredient means a cosmetic or pharmaceutical ingredient having cosmetic and/or pharmaceutical efficacy. Active pharmaceutical ingredients correspond to active pharmaceutical principles. Categories and examples of cosmetic and/or pharmaceutical active ingredients are provided below.
  • suitable cosmetic or pharmaceutical vehicle means that the composition or the components thereof are suitable for use in contact with human skin and/or mucous membranes without toxicity, incompatibility, instability, allergic response, or their equivalents, undue.
  • the combination according to the invention comprises, in particular consists of:
  • alginic acid one of its salts or derivatives, advantageously propylene glycol alginate,
  • sucrose one of its salts or derivatives, advantageously sucrose. It therefore comprises, in particular it consists of, 6 ingredients.
  • the combination according to the invention and preferably in the form of the 6 compounds (pullulan or its derivative, hyaluronic acid or its salt or derivative, alginic acid or its salt or derivative, lactic acid or its salt or derivative, succinic acid or its or derivative and sucrose or its derivative) is preferably used alone or in the form of a mixture of cosmetic or pharmaceutical ingredients further comprising a cosmetic or pharmaceutical vehicle, in particular dermatological, suitable for its formulation and/or for its integration into a composition cosmetic or pharmaceutical, in particular dermatological.
  • the combination according to the invention can also be used in a cosmetic or pharmaceutical composition, in particular dermatological, that is to say with an appropriate cosmetic or pharmaceutical vehicle, in particular appropriate dermatological, and preferably intended for administration by topical route.
  • said combination according to the invention comprises, in particular consists of a mixture of the 6 compounds (pullulan or its derivative, hyaluronic acid or its salt or derivative, alginic acid or its salt or derivative, lactic acid or its salt or derivative, succinic acid or its salt or derivative and sucrose or its salt or derivative) preferably at a ratio lying in the range l/l/l/l/l to 1/10/10/300/100 /300, and more preferably in the range 1/1/1/10/5/10 to 1/2/5/100/50/100, more preferably in the range 1/1/1/20/5/20 to 1/1/2/30/10/35, advantageously a ratio of 1/1/2/24/8/30.
  • the combination according to the invention is in the form of a mixture of cosmetic or pharmaceutical ingredients, in particular dermatological ingredients, advantageously intended to be incorporated into a cosmetic composition or pharmaceutical, in particular dermatological, further comprising an appropriate cosmetic or pharmaceutical vehicle.
  • the vehicle for the mixture of cosmetic or pharmaceutical ingredients is and/or contains water.
  • the present invention further relates to a mixture of cosmetic or pharmaceutical ingredients intended to be incorporated into a cosmetic or pharmaceutical composition, said mixture comprising the combination according to the invention and an appropriate cosmetic or pharmaceutical vehicle.
  • the combination according to the invention is included in the mixture of cosmetic or pharmaceutical ingredients, in particular dermatological, at a content of 0.001% to 30% by weight of dry matter relative to the total weight of the mixture of cosmetic or pharmaceutical ingredients. , more advantageously between 0.01 and 20% by weight, even more advantageously between 0.1 and 20% by weight, in particular between 0.25 and 20% by weight, more particularly between 1 and 20% by weight of dry matter relative to the total weight of the mixture of cosmetic or pharmaceutical ingredients, preferably in combination with glycerin and/or xanthan gum and/or pentylene glycol, and/or caprylyl glycol and/or water, again advantageously xanthan gum and/or glycerine.
  • the mixture of cosmetic or pharmaceutical, in particular dermatological, ingredients comprises on the one hand: pullulan or one of its cosmetically or pharmaceutically acceptable derivatives in a content of between 0.0001 and 10% by weight of dry matter per relative to the total weight of the mixture of ingredients, more advantageously between 0.001% and 5% by weight, even more advantageously between 0.01 and 3% by weight, in particular between 0.1 and 1% by weight, even more particularly between 0.25 and 0.5% by weight, very particularly 0.25% by weight relative to the total weight of the mixture of ingredients and
  • - hyaluronic acid or one of its cosmetically or pharmaceutically acceptable salts or derivatives in a content of between 0.0001 and 10% by weight of dry matter relative to the total weight of the mixture of ingredients, advantageously between 0.001% and 5% by weight, more advantageously between 0.01 and 3% by weight, in particular between 0.1 and 1% by weight, more particularly between 0.1 and 1% by weight, even more particularly between 0.25 and 0.5 % by weight, very particularly 0.25% by weight relative to the total weight of the mixture of ingredients and/or
  • sucrose or one of its cosmetically or pharmaceutically acceptable salts or derivatives in a content of between 1 and 15% by weight of dry matter relative to the total weight of the mixture of ingredients, advantageously between 3 and 9% by weight, even more particularly 7.5% by weight relative to the total weight of the mixture of ingredients.
  • the mixture of cosmetic or pharmaceutical ingredients comprises the combination of pullulan or of one of its derivatives, of hyaluronic acid or of one of its salts or derivatives and of alginic acid or of a of its salts or derivatives, preferably at a ratio of between 1/1/1 and 1/10/10, preferably of between 1/1/1 and 1/2/5, more preferably at a ratio of 1/1/2 .
  • the mixture of cosmetic or pharmaceutical ingredients according to the invention also comprises xanthan gum and/or glycerin and/or water.
  • the mixture of cosmetic or pharmaceutical ingredients according to the invention is in liquid form.
  • the mixture of cosmetic or pharmaceutical ingredients according to the invention then contains a polar solvent, such as water, an alcohol, a polyol, a glycol, such as pentylene glycol and/or butylene glycol and/or hexylene glycol and/or caprylyl glycol, or one of their mixtures, preferably a hydroglycolic mixture, more preferably containing a glycol chosen from hexylene glycol, pentylene glycol, caprylyl glycol and mixtures thereof, or glycerol.
  • a polar solvent such as water, an alcohol, a polyol, a glycol, such as pentylene glycol and/or butylene glycol and/or hexylene glycol and/or caprylyl glycol, or one of their mixtures, preferably a hydroglycolic mixture, more preferably containing a glycol chosen from hexylene glycol, pentylene glycol, caprylyl glycol and mixtures thereof, or g
  • the mixture of cosmetic or pharmaceutical ingredients contains pentylene glycol, in particular between 0.1 and 10%, preferably between 0.5 and 5%, more preferably between 1 and 3% by weight of pentylene glycol, relative to the weight total of the mixture of cosmetic ingredients.
  • the mixture of ingredients contains caprylyl glycol, in particular containing between 0.01 and 10%, preferably between 0.1 and 5%, more preferably between 0.3 and 1% by weight of caprylyl glycol, relative to the total weight of the mixture of cosmetic ingredients.
  • the combination, in particular in the form of the mixture of cosmetic or pharmaceutical, in particular dermatological, ingredients according to the invention can be used in a cosmetic or pharmaceutical, in particular dermatological, composition, preferably at a content by weight of dry matter relative to the total weight of the composition between 0.1 and 10%, advantageously between 0.1 and 5%, in particular between 0.1 and 3%.
  • the present invention further relates to a cosmetic or pharmaceutical composition intended for topical administration comprising the combination according to the invention or the mixture of cosmetic or pharmaceutical ingredients according to the invention and an appropriate cosmetic or pharmaceutical vehicle.
  • the cosmetic or pharmaceutical composition according to the invention additionally comprises xanthan gum and/or glycerin and/or pentylene glycol and/or caprylyl glycol.
  • the combination according to the invention or the mixture of cosmetic or pharmaceutical ingredients comprising it according to the invention is in the form of a cosmetic or pharmaceutical composition, in particular dermatological, intended for topical administration further comprising an appropriate cosmetic or pharmaceutical vehicle.
  • the combination according to the invention is included in a cosmetic or pharmaceutical composition, in particular dermatological, in particular intended to be administered to a human being, preferentially by topical application, preferentially cutaneous.
  • the combination according to the present invention is then included in the composition at a content of between 0.0001% and 20% by weight of total dry matter relative to the total weight of the composition, between 0.0005% and 10%, plus advantageously between 0.005 and 10% by weight, even more advantageously between 0.005 and 5% by weight, in particular between 0.005 and 1% by weight, of total dry matter relative to the total weight of the composition.
  • the cosmetic or pharmaceutical composition according to the invention, in particular dermatological preferably also contains a vehicle and/or cosmetic and/or pharmaceutical, in particular dermatological, excipient.
  • - lactic acid or one of its cosmetically or pharmaceutically acceptable salts or derivatives in a content of between 0.001 and 10% by weight of dry matter relative to the total weight of the mixture of ingredients, advantageously between 0.001 and 5% by weight, more preferably between 0.01 and 1% by weight, even more advantageous between 0.1 and 0.5% by weight, even more particularly 0.12% by weight and
  • sucrose or cosmetically or pharmaceutically acceptable derivatives in a content of between 0.001 and 10% by weight of dry matter relative to the total weight of the mixture of ingredients, advantageously between 0.001 and 5% by weight, more advantageously between 0.01 and 1% by weight, even more advantageously between 0.1 and 0.5% by weight, even more particularly 0.15% by weight.
  • the cosmetic or pharmaceutical composition contains the combination of pullulan or one of its derivatives, hyaluronic acid, or one of its salts or derivatives and alginic acid or one of its salts or derivatives, preferably at a ratio of 1/1/2.
  • the composition is in the form of a serum, a lotion, a cream, a milk, an ointment, a paste, a mousse, an emulsion, a hydrogel, a shower gel, a mask, a stick, a patch, or makeup powders, advantageously a cream or a lotion.
  • compositions according to the invention may contain any suitable solvent and/or any suitable vehicle and/or any suitable excipient, optionally in combination with other compounds of interest. They may in particular contain a cosmetically or dermatologically acceptable excipient chosen from surfactants, preservatives, buffering agents, swelling agents, chelating agents, biocidal agents, denaturants, opacifying agents, pH adjusters, reducing agents , stabilizers, emulsifiers, thickeners, gelling agents, film-forming polymers, solvents, fillers, bactericides, odor absorbers, matting agents, conditioning agents, texture agents, shine agents , pigments, dyes, perfumes and chemical or mineral sunscreens, trace elements, essential oils. These combinations are also covered by the present invention.
  • CTFA Cosmetic Ingredient Handbook, Second Edition (1992) describes various cosmetic and pharmaceutical ingredients commonly used in the cosmetic and pharmaceutical industry, which are particularly suitable for topical use.
  • compositions according to the invention in the form of a mixture of cosmetic or pharmaceutical ingredients or of cosmetic or pharmaceutical composition contain at least one other cosmetic or pharmaceutical active ingredient, in particular dermatological, and preferably from one to three ingredients cosmetic or pharmaceutical active agents, in particular dermatological active agents, preferably having complementary properties on the virulence factors and/or on the unsightly and/or unpleasant and/or uncomfortable manifestations due to the virulence of C.
  • acnes in particular the secretion of sebum, the formation of blackheads and/or comedogenesis, the visibility of skin pores, the homogeneity and/or radiance and/or luminosity of the complexion of the skin and/or mucous membranes, the sensation of heating of the skin and/or mucous membranes, hair loss and/or body hair and/or the appearance of dandruff.
  • These may be cosmetic ingredients having a complementary effect such as those chosen from salicylic acid, niacinamide, zinc gluconate, an extract of Bixa oreiiana seeds (for example Bix-ActivTM) and/or N -methyl glycine (e.g. ScalposineTM).
  • the present invention also relates to the cosmetic use of the combination according to the invention or of the mixture of cosmetic ingredients according to the invention or of the cosmetic composition according to the invention for limiting and/or reducing the virulence of Cutibacterium acnes on the skin and/or mucous membranes, in particular by at least one of the following mechanisms:
  • the cosmetic use according to the invention is to prevent and/or reduce and/or eliminate the unsightly and/or unpleasant and/or uncomfortable manifestations due to the virulence of C. acnes, in particular to prevent and/or reduce and/or delay the secretion of sebum and its unsightly and/or unpleasant and/or uncomfortable manifestations, in particular to prevent and/or reduce and/or delay the formation of blackheads and/or comedogenesis, prevent and /or reduce the visibility of skin pores and/or maintain and/or improve the evenness and/or radiance and/or luminosity of the complexion of the skin and/or mucous membranes, and/or prevent and/or treat sensation of heating of the skin and/or mucous membranes, and/or to prevent and/or reduce hair loss and/or body hair and/or to prevent and/or reduce dandruff.
  • the combination, the mixture of cosmetic or pharmaceutical, in particular dermatological, ingredients according to the invention is topically acceptable.
  • topically acceptable means an ingredient suitable for application respectively by topical route, non-toxic, non-irritating to the skin and/or the mucous membranes and/or the scalp, not inducing allergic response, which is not chemically unstable.
  • the combination according to the invention is also very particularly suitable for use on the mucous membranes, alone or in the form of a cosmetic or dermatological composition, in particular for limiting and/or reducing the mucosal virulence of Cutibacterium acnes, advantageously for preventing and/or reducing and/or remove the unsightly and/or unpleasant and/or uncomfortable manifestations due to the virulence of Cutibacterium acnes, in particular to maintain and/or increase and/or improve the homogeneity and/or the radiance and/or the luminosity of the complexion of the mucous membranes and/or preventing and/or treating the sensation of heating of the mucous membranes.
  • the combination according to the invention can be applied to all or part of the human body, preferably chosen from the body, the face, in particular the forehead, the cheeks, the chin, the nose, the so-called “T” zone (forehead, nose and chin), the neck and the contour of the lips, the scalp, the shoulders, the arms, the back, the torso, the Vietnameselleté , the ocular mucosa, the nasal mucosa, the oral mucosa, in particular the labial buccal mucosa and/or the gingival mucosa, the excessively cleaned areas and/or the area of skin or mucous membrane whose skin barrier has been altered, for example due to a mechanical, chemical or biological action, such as sunburn (erythema solar), by the action of the razor, by the use of unsuitable or too astringent cleaning products, by pollution, by the use antibiotics, allergens, etc.
  • the present invention further relates to the combination according to the invention, advantageously in the form of a mixture of pharmaceutical ingredients or in the form of a pharmaceutical composition, in particular dermatological, according to the present invention for its use as a pharmaceutical active ingredient, in particular dermatological, in particular in the treatment and/or the prevention and/or the reduction in the occurrence of pathologies due to the virulence of C. acnes, advantageously involving an increase in the secretion of biofilm and/or an increase in adhesion of C.
  • acnes advantageously from pathologies chosen from the group consisting of bacterial infections of the skin and/or mucous membranes, pustules, papules, boils, folliculitis, abscesses, acne, in particular superinfected, wounds in particularly superinfected, inflammation of the skin and/or mucous membranes, and/or in the prevention of scar marks, in particular pigment spots and/or acne scars.
  • the present invention relates to a method of cosmetic care (and therefore non-therapeutic), characterized in that it comprises the application to at least one zone concerned of the skin and/or of the mucous membranes of the face and/or of the body, of the combination according to the present invention or of a cosmetic composition or of a mixture of cosmetic ingredients comprising, as active agent, the combination according to the invention as defined previously, to prevent and/or reduce and/ or suppress the unsightly and/or unpleasant and/or uncomfortable manifestations due to the virulence of Cutibacterium acnes, in particular the formation of biofilm, in particular to prevent and/or reduce and/or delay the secretion of sebum and its unsightly manifestations and/or unpleasant and/or uncomfortable, more particularly for preventing and/or reducing and/or delaying the formation of blackheads and/or comedogenesis, and/or preventing and/or reducing the visibility of skin pores and/or maintaining and/or improving the homogeneity and/or the radiance and/or the luminosity of the complexion
  • the present invention further relates to a cosmetic (and therefore non-therapeutic) care method for preventing and/or reducing and/or eliminating the unsightly and/or unpleasant and/or uncomfortable manifestations due to the virulence of Cutibacterium acnes, in particular the formation of biofilm, in particular for preventing and/or reducing and/or delaying the secretion of sebum and its unsightly and/or unpleasant and/or uncomfortable manifestations, more particularly for preventing and/or reducing and/or delaying the formation of blackheads and/ or comedogenesis, and/or prevent and/or reduce the visibility of skin pores and/or maintaining and/or improving the uniformity and/or the radiance and/or the luminosity of the complexion of the skin and/or the mucous membranes, and/or preventing and/or treating the sensation of skin heating and /or mucous membranes, and/or to prevent and/or reduce hair loss and/or body hair, and/or to prevent and/or reduce dandruff, characterized in that it comprises the
  • the method comprises the selection of an area of the skin and/or of the mucous membranes for which it is necessary to prevent and/or reduce and/or eliminate the unsightly and/or unpleasant and/or uncomfortable manifestations due to the virulence of Cutibacterium acnes, more particularly the formation of the biofilm, in particular to delay the secretion of sebum and its unsightly and/or unpleasant and/or uncomfortable manifestations, more particularly to reduce and/or delay the formation of blackheads and/or the comedogenesis, and/or preventing and/or reducing the visibility of skin pores and/or maintaining and/or improving the evenness and/or radiance and/or luminosity of skin tone and/or mucous membranes, and/or to prevent and/or treat the feeling of skin and/or mucous membrane heating, and/or to prevent and/or reduce hair loss and/or body hair, and/or to prevent and / or reduce dandruff, before application, of the combination according to the present invention or of a cosmetic composition or of a mixture
  • the area concerned of the skin and/or mucous membranes of the face or of the body is chosen from all or part of the human body, preferentially chosen from among the body, the face, in particular the forehead, the cheeks, the chin, the nose, the so-called “T” zone (forehead, nose and chin), the neck and the contour of the lips, the scalp, the shoulders, arms, back, torso, Vietnameselletage, ocular mucosa, nasal mucosa, oral mucosa, including labial buccal mucosa and/or gingival mucosa, excessively cleansed areas and/or skin area or of mucous membrane whose skin barrier has been altered, for example due to a mechanical, chemical or biological action, such as sunburn (erythema solar), by the action of the razor, by the use of cleaning products unsuitable or too astringent, by pollution, by the use of antibiotics, by allergens etc....
  • a mechanical, chemical or biological action such as sunburn (erythema solar
  • It also relates to a method for treating and/or preventing and/or reducing the occurrence of pathologies due to the virulence of C acnes, advantageously involving an increase in the secretion of biofilm and/or an increase in the adhesion of C.
  • acnes advantageously from pathologies chosen from the group consisting of bacterial infections of the skin and/or mucous membranes, pustules, papules, boils, folliculitis, abscesses, acne, in particular superinfected, wounds in particular superinfected, inflammation of the skin and/or mucous membranes, and/or in the prevention of scar marks, in particular pigment spots and/or acne scars, advantageously by application to at least one affected area of the skin and/or mucous membranes of the face or body of a patient in need thereof, of an effective quantity of the combination according to the present invention or of a pharmaceutical composition or of a mixture of pharmaceutical ingredients comprising, as active agent, the combination according to the invention as defined above.
  • the temperature is expressed in degrees Celsius and the pressure is atmospheric pressure.
  • Example 2 Evaluation of the inhibition of the product according to the invention on the formation of biofilm by C acnes.
  • Cutibacterium acnes was taken from human skin (face) and type I phylotyped with the MLST (MultiLocus Sequencing Typing) method (bacteria known as IA2 from the company Biofilm Control). It was grown on an agar plate under anaerobic conditions.
  • MLST MultiLocus Sequencing Typing
  • Product Cl corresponds to the product according to Example 1 devoid of the 3 compounds: succinic acid, lactic acid and sucrose and whose composition is indicated in the following table 2:
  • Product C2 corresponds to the 3 compounds removed from the product of Example 1 (and absent from product C1) and whose composition is indicated in Table 3 below:
  • the initial bacterial suspension was prepared in BHI (Brain Heart Infusion) type culture medium, inoculated at 10 6 CFU/mL estimated by absorbance measurement (OD 600 nm) and each well was filled with magnetic beads (TON004) at 10 pL/mL.
  • Negative controls were prepared by mixing BHI with TON004 (10 ⁇ L/mL). Controls were also present in parallel to evaluate the mobility of the microbeads in the presence of the ingredients alone.
  • the microplates were incubated under anaerobic conditions at 37°C. After 56 hours, a contrast liquid was added to each well and the microplate was magnetized for 1 min on the Block Test. The microplate was then scanned and analyzed with BFC Elements 3.0 software. When the biofilm is formed the beads cannot move in the well. This corresponds to a biofilm formed at the height of 100%. In the presence of ingredients inhibiting the formation of the biofilm, the beads will be able to aggregate in the center of the well. The rate of beads aggregating in the center of the well corresponds to the percentage of inhibition of the formation of the biofilm.
  • the results are presented as percentage of formation of the biofilm of C. acnes.
  • the positive control corresponds to 100% of biofilm formed by the C. acnes bacteria alone.
  • Example 3 Evaluation of the inhibition of adhesion on C acnes by the product according to the invention.
  • the C. acnes bacterium deposited in culture under the number ATCC6919 was cultured anaerobically for 72 hours at 37° C. in non-selective culture medium (Schaedler) in the absence (known as “untreated control”) or in the presence of the Product according to Example 1 at 1% by volume relative to the total volume (culture medium + Product according to Example 1).
  • the cultures were placed in anaerobic conditions for 6 h at 37° C. to allow bacterial adhesion. Then, labeling with Syto9 was carried out to allow observation of the adherent bacteria under a confocal microscope (excitation/emission: 485/498 nm).
  • Biomass analysis was performed with ComStat2 software. It is a calculation of volume in pm 3 /pm 2 (corresponds to the biomass (in pm 3 ) divided by the surface in pm 2 ). Count of the volume of Biomass in pm 3 /pm 2 SEM T-test vs untreated control.
  • n 11; Avg. denotes the mean. SEM designates the deviation from the mean. The statistical test used is the t test performed versus the untreated control with a significance level p ⁇ 0.01. S denotes a significant deviation from the mean.
  • the product according to the invention inhibits the adhesion of C. acnes without impacting the viability of C. acnes.
  • Example 4 Mixture of cosmetic or pharmaceutical ingredients according to the invention containing the combination according to the invention
  • a mixture of cosmetic or pharmaceutical ingredients having the formulation indicated in table 6 below in percentage by weight is prepared.
  • Pentylene glycol, caprylyl glycol, glycerin, lactic acid, succinic acid and sucrose are dissolved in water beforehand.
  • the polymers hyaluronic acid, pullulan, propylene glycol alginate and xanthan gum
  • the mixture obtained is kept under stirring until a homogeneous product is obtained.
  • Example 5 Composition according to the invention in the form of a lotion for the body and/or the face
  • the lotion is prepared by the usual methods in the field well known to those skilled in the art, by mixing the 6 phases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
EP23706401.9A 2022-01-25 2023-01-24 Inhaltsstoff zum schutz der haut und/oder schleimhäute vor virulenzfaktoren Pending EP4469019A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2200627A FR3132023B1 (fr) 2022-01-25 2022-01-25 Ingredient protecteur de la peau et/ou des muqueuses contre les facteurs de virulence
PCT/FR2023/050094 WO2023144487A1 (fr) 2022-01-25 2023-01-24 Ingredient protecteur de la peau et/ou des muqueuses contre les facteurs de virulence

Publications (1)

Publication Number Publication Date
EP4469019A1 true EP4469019A1 (de) 2024-12-04

Family

ID=81325006

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23706401.9A Pending EP4469019A1 (de) 2022-01-25 2023-01-24 Inhaltsstoff zum schutz der haut und/oder schleimhäute vor virulenzfaktoren

Country Status (4)

Country Link
EP (1) EP4469019A1 (de)
CN (1) CN118591367A (de)
FR (1) FR3132023B1 (de)
WO (1) WO2023144487A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2654255A1 (en) 2006-06-28 2008-01-03 Novozymes Biopolymer A/S Compositions with several hyaluronic acid fractions for cosmetic and medical uses
FR2994387B1 (fr) 2012-08-13 2016-07-29 Basf Beauty Care Solutions France Sas Ingredient hydratant cosmetique ou pharmaceutique
FR3064473B1 (fr) 2017-04-03 2021-02-12 Basf Beauty Care Solutions France Sas Ingredient protecteur de l'equilibre de la flore microbienne cutanee et/ou mucosale
US10675234B1 (en) * 2019-02-22 2020-06-09 N.V. Perricone Llc Systems and methods for treating and/or preventing acne

Also Published As

Publication number Publication date
FR3132023A1 (fr) 2023-07-28
WO2023144487A1 (fr) 2023-08-03
FR3132023B1 (fr) 2024-01-05
CN118591367A (zh) 2024-09-03

Similar Documents

Publication Publication Date Title
EP2882415B1 (de) Feuchtigkeitsspendender bestandteil eines kosmetikums oder pharmazeutikums
EP2303300B1 (de) Zusammensetzungen zur förderung der entwicklung und des wachstums einer günstigen vaginalen mikroflora
EP2155149A2 (de) Pharmazeutische oder kosmetische präparate zur topischen und/oder parenteralen anwendung, verfahren zu ihrer herstellung und ihre anwendung
WO2008139122A2 (fr) Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
BE1010042A3 (fr) Utilisation d'un extrait d'eriobotrya japonica, notamment dans le domaine de la cosmetique, pour stimuler la synthese des glycosaminoglycanes.
FR3076460A1 (fr) Utilisation cosmetique d'un extrait proteique des graines de moringa oleifera
WO2018185408A1 (fr) Ingredient protecteur de l'equilibre de la flore microbienne cutanee et/ou mucosale
FR3018191A1 (fr) Utilisations cosmetiques de la swertiamarine
EP2731585B1 (de) Verwendung von oligosacchariden zur prävention und behandlung von pathologischen narben
EP2148727A2 (de) Pharmazeutische oder kosmetische präparate zur topischen und/oder parenteralen anwendung, verfahren zu ihrer herstellung und ihre anwendung
EP2833863A1 (de) Neuartige oligosaccharidverbindungen und kosmetische verwendung davon
EP3908267B1 (de) Produkt zur behandlung von dysbiosen
FR2989892A1 (fr) Composition cosmetique comprenant un oligosaccharide phosphoryle et un polysaccharide
FR3112953A1 (fr) Utilisation cosmétique du sacran
EP4277593B1 (de) Kosmetisches verfahren und zusammensetzung auf basis von kurzkettigen fructooligosacchariden und einer nativen stärke
FR3010306A1 (fr) Composition cosmetique comprenant un systeme lamellaire
EP3764977A1 (de) Kosmetische formulierung
EP2376055B1 (de) Kosmetische Zusammensetzung mit einem Johannisbrotgumhydrolysat
EP2954902B1 (de) Zusammensetzung auf der basis von grapefruitkern-, frauenmantel-, stevia- und kurkuminextrakt
WO2021224575A1 (fr) Composition cosmetique comprenant au moins une algue rouge calcaire
EP4469019A1 (de) Inhaltsstoff zum schutz der haut und/oder schleimhäute vor virulenzfaktoren
BE1030448B1 (fr) Complexe glutamine acide - tannique
CA2953260C (fr) Produits de combinaison et compositions cosmetiques pour lutter contre les desordres de la peau et son vieillissement affectant les keratinocytes et/ou les fibroblastes et le derme
FR2989274A1 (fr) Composition cosmetique cutanee et/ou dermatologique destinee a limiter l'adhesion des bacteries pathogenes au niveau de la peau
FR2917971A1 (fr) Composition amincissante

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240826

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)